Skip to main content

Medicenna Therapeutics Corp.

MDNAF
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001807983

No open-market purchases or sales by Medicenna Therapeutics Corp. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Q2 2023 vs. Q1 2023

How the institutions holding Medicenna Therapeutics Corp. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of MDNAF: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders28280
Shares9.76M10.9M+1.19M (+12.1%)
Value$6.25M$4.75M−$1.50M (−24.0%)

New holders (3)

Institutions that held Medicenna Therapeutics Corp. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to MDNAF in Q2 2023
InstitutionSharesValue% of portfolio
Susquehanna International Group, LLP53,732$25.7K0.00%
Virtu Financial LLC21,530$10.0K0.00%
National Bank of Canada600$2720.00%

Sold out (3)

Institutions that held Medicenna Therapeutics Corp. at the end of Q1 2023 and filed for Q2 2023 without it.

Institutions that sold out of MDNAF in Q2 2023
InstitutionShares, Q1 2023Value, Q1 2023
Millennium Management LLC68,215$44.0K
Belpointe Asset Management LLC10,249$6.45K
Advisory Services Network, LLC747$470